Close Menu

In PLoS One this week, MIT researchers say they've developed the first ever broad-spectrum antiviral therapeutic. Instead of taking a pathogen-specific approach to developing antivirals, the team has created a new approach, called Double-Stranded RNA Activated Caspase Oligomerizer, or DRACO, which selectively induces apoptosis in cells that contain viral dsRNA, and kills infected cells without harming normal cells.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.